| 前收市價 | 19.56 |
| 開市 | 18.78 |
| 買盤 | 19.12 x 1400 |
| 賣出價 | 19.43 x 1400 |
| 今日波幅 | 18.72 - 19.30 |
| 52 週波幅 | 3.53 - 23.86 |
| 成交量 | |
| 平均成交量 | 13,941,723 |
| 市值 | 2.833B |
| Beta 值 (5 年，每月) | 1.95 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -3.05 |
| 業績公佈日 | 2024年8月06日 - 2024年8月12日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 21.60 |
Yahoo FinanceNovavax's stock surges almost 300% in the past month
Novavax stock is soaring on news the FDA set a deadline by which to approve or reject its COVID-19 vaccine.
Investor's Business DailyNovavax, With A 369% Gain, Reverses Bullish Gains After Key FDA Move
Novavax stock zipped higher and then plunged Thursday after the FDA set a potential approval date for its Covid vaccine in April.
Barrons.comNew Covid Boosters Get a Thumbs-Up From FDA. Vaccine Stocks Are Wavering.
Drugmakers are aiming to launch this year’s shots by the beginning of September but have been waiting on the FDA to decide which strain of the virus to target. At their meeting on Wednesday, the FDA’s advisers nevertheless recommended that this year’s shots target JN.1, saying they expect a JN.1 shot to offer sufficient protection against the strain’s descendants.
